A recently-approved breast cancer drug could be used to target and treat a life-threatening leukaemia, new research has revealed.
Experts at Newcastle University, UK, have identified that the drug, palbociclib, used for advanced breast cancer, can work effectively on treating acute myeloid leukaemia (AML).
Unlike current chemotherapy used to fight AML, palbociclib has significantly less toxic side-effects, such as irreversible heart damage and hair loss.
The study carried out on cell lines in the laboratory and on a mouse model, is published today in Cancer Cell and is a key step towards targeted treatment for adults and children with the serious condition.
It is hoped that this research development could increase survival rates for patients in the future.
Professor Olaf Heidenreich, from the Wolfson Childhood Cancer Research Centre at Newcastle University, led the European study.
He said: “Last year, palbociclib was approved for use in patients and was hailed by many experts as the most important breakthrough for women with advanced breast cancer in years.
“Our discovery that this treatment can be effective in AML is an important step towards a more effective and less toxic treatment for patients with this form of leukaemia.
“In addition to
Article originally posted at